Term
|
Definition
| ADRs of Lamivudine and Emtricitabine (NRTIs) |
|
|
Term
hypersensitivity reaction
have to test patient for HLA-B 5701 to see if they are at an increased risk of the hypersensitivity reaction |
|
Definition
|
|
Term
| Myelosuppression - seen as neutropenia from CBC |
|
Definition
|
|
Term
pancreatitis
peripheral neuropathy |
|
Definition
| ADR of Didanosine and Stavudine (NRTIs) |
|
|
Term
|
Definition
|
|
Term
hepatic metabolism
hepatic dosing adjustment unknown
CYP3A4 DRUG INTERACTIONS
no renal dosing
class side effect: rash |
|
Definition
| common ADRs of NNRTIs (nevirapine, delavirdine, efavirenz, etravirine) |
|
|
Term
pregnancy category D
neuropsychiatric effects |
|
Definition
| ADRs of Efavirenz (NNRTI) |
|
|
Term
women CD4 count < 250
men CD4 count < 400 |
|
Definition
| ADRs of Nevirapine (NNRTI) |
|
|
Term
hepatic metabolism
no renal dosing, except atazanavir in HD
notorious for CYP3A4 DRUG INTERACTIONS
GI ADRs common, most require administration with food (except indinavir which is administered on an empty stomach)
rash: common with darunavir and tipranavir (sulfonamide moieties), amprenavir, fosamprenavir
hyperglycemia
fat maldistribution
possible increased bleeding episodes in patients with hemophilia
diarrhea: common with fosamprenavir, lopinavir/ritonavir, nelfinavir, tipranavir
increased liver enzymes: common with tiprinavir
increased cholesterol and TGs: common with ritonavir |
|
Definition
|
|
Term
|
Definition
| ADRs of Enfuvirtide (fusion inhibitor) |
|
|
Term
|
Definition
| ADR of Maraviroc (entry inhibitor) |
|
|
